SCHEMBL2929906

SCHEMBL2929906

CCOC(=O)c1nc2sc(C)cn2c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 2/20 0.44
MAPK1 P28482 2/20 0.43
MAPT P10636 4/20 0.41
ELANE P08246 2/20 0.41
TP53 P04637 4/20 0.40
F2 P00734 1/20 0.40
PLAU P00749 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
GAA P10253 2/20 0.40
ALOX12 P18054 1/20 0.40
POLB P06746 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
XBP1 P17861 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927059 0.79 KDM4E (0.41) ALDH1A1CYP1A2MAPTTP53POLB
SCHEMBL1340023 0.79 MAPK1 (0.61) ALDH1A1CYP1A2MAPK1MAPTTP53
SCHEMBL1339451 0.77 MAPK1 (0.67) ALDH1A1CYP1A2MAPK1MAPTELANE
SCHEMBL11487200 0.75 MAPT (0.44) ALDH1A1MAPTTP53POLBSMN1; SMN2
SCHEMBL10339173 0.74 ALDH1A1 (0.45) ALDH1A1CYP1A2MAPK1MAPTTP53
SCHEMBL1339869 0.73 IDO1 (0.46) ALDH1A1MAPK1MAPTGAAPOLB
SCHEMBL11323481 0.73 GAA (0.52) ALDH1A1CYP1A2MAPK1MAPTGAA
SCHEMBL19798100 0.72 MAPT (0.37) ALDH1A1MAPTTP53POLBNPC1
SCHEMBL2932004 0.72 ALDH1A1 (0.46) ALDH1A1CYP1A2MAPK1MAPTELANE
SCHEMBL24066043 0.71 GAA (0.44) ALDH1A1CYP1A2MAPK1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 EP disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 EP disclosed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 ALDH1A1 702/4885CYP1A2 558/4885MAPK1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.